These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

428 related articles for article (PubMed ID: 32065376)

  • 21. Silymarin: not just another antioxidant.
    Camini FC; Costa DC
    J Basic Clin Physiol Pharmacol; 2020 Mar; 31(4):. PubMed ID: 32134732
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Silymarin retards the progression of alcohol-induced hepatic fibrosis in baboons.
    Lieber CS; Leo MA; Cao Q; Ren C; DeCarli LM
    J Clin Gastroenterol; 2003 Oct; 37(4):336-9. PubMed ID: 14506392
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of Oral Administration of Silymarin in a Juvenile Murine Model of Non-alcoholic Steatohepatitis.
    Marin V; Gazzin S; Gambaro SE; Dal Ben M; Calligaris S; Anese M; Raseni A; Avellini C; Giraudi PJ; Tiribelli C; Rosso N
    Nutrients; 2017 Sep; 9(9):. PubMed ID: 28895929
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Affect of silymarin on serum levels of ALT and GGT in ethanol induced hepatotoxicity in albino rats.
    Habib-ur-Rehman M; Mahmood T; Salim T; Afzal N; Ali N; Iqbal J; Tahir M; Khan A
    J Ayub Med Coll Abbottabad; 2009; 21(4):73-5. PubMed ID: 21067030
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hepatoprotective and antiviral functions of silymarin components in hepatitis C virus infection.
    Polyak SJ; Ferenci P; Pawlotsky JM
    Hepatology; 2013 Mar; 57(3):1262-71. PubMed ID: 23213025
    [No Abstract]   [Full Text] [Related]  

  • 26. Chemoprotective effect of plant phenolics against anthracycline-induced toxicity on rat cardiomyocytes. Part I. Silymarin and its flavonolignans.
    Chlopcíková S; Psotová J; Miketová P; Simánek V
    Phytother Res; 2004 Feb; 18(2):107-10. PubMed ID: 15022159
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of silymarin on the resolution of liver fibrosis induced by carbon tetrachloride in rats.
    Tsai JH; Liu JY; Wu TT; Ho PC; Huang CY; Shyu JC; Hsieh YS; Tsai CC; Liu YC
    J Viral Hepat; 2008 Jul; 15(7):508-14. PubMed ID: 18397225
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Silymarin in non-cirrhotics with non-alcoholic steatohepatitis: A randomized, double-blind, placebo controlled trial.
    Navarro VJ; Belle SH; D'Amato M; Adfhal N; Brunt EM; Fried MW; Reddy KR; Wahed AS; Harrison S;
    PLoS One; 2019; 14(9):e0221683. PubMed ID: 31536511
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Oxidative stress and antioxidant defense in alcoholic liver disease and chronic hepatitis C].
    Pár A; Róth E; Rumi G; Kovács Z; Nemes J; Mózsik G
    Orv Hetil; 2000 Jul; 141(30):1655-9. PubMed ID: 10962902
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Milk thistle in liver diseases: past, present, future.
    Abenavoli L; Capasso R; Milic N; Capasso F
    Phytother Res; 2010 Oct; 24(10):1423-32. PubMed ID: 20564545
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Silymarin liposomes improves oral bioavailability of silybin besides targeting hepatocytes, and immune cells.
    Kumar N; Rai A; Reddy ND; Raj PV; Jain P; Deshpande P; Mathew G; Kutty NG; Udupa N; Rao CM
    Pharmacol Rep; 2014 Oct; 66(5):788-98. PubMed ID: 25149982
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of silymarin nanoemulsion against carbon tetrachloride-induced hepatic damage.
    Parveen R; Baboota S; Ali J; Ahuja A; Vasudev SS; Ahmad S
    Arch Pharm Res; 2011 May; 34(5):767-74. PubMed ID: 21656362
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Drug clinics. Drug of the month. Legalon (silymarin)].
    Luyckx F; Scheen AJ
    Rev Med Liege; 1997 Dec; 52(12):792-6. PubMed ID: 9481179
    [No Abstract]   [Full Text] [Related]  

  • 34. Resolution of liver fibrosis in chronic CCl4 administration in the rat after discontinuation of treatment: effect of silymarin, silibinin, colchicine and trimethylcolchicinic acid.
    Muriel P; Moreno MG; Hernández Mdel C; Chávez E; Alcantar LK
    Basic Clin Pharmacol Toxicol; 2005 May; 96(5):375-80. PubMed ID: 15853930
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver.
    Ferenci P; Dragosics B; Dittrich H; Frank H; Benda L; Lochs H; Meryn S; Base W; Schneider B
    J Hepatol; 1989 Jul; 9(1):105-13. PubMed ID: 2671116
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Silymarin-loaded Eudragit(®) RS100 nanoparticles improved the ability of silymarin to resolve hepatic fibrosis in bile duct ligated rats.
    Younis N; Shaheen MA; Abdallah MH
    Biomed Pharmacother; 2016 Jul; 81():93-103. PubMed ID: 27261582
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Silymarin and its constituents in cardiac preconditioning.
    Zholobenko A; Modriansky M
    Fitoterapia; 2014 Sep; 97():122-32. PubMed ID: 24879900
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Liver-protective action of silymarin therapy in chronic alcoholic liver diseases].
    Fehér J; Deák G; Müzes G; Láng I; Niederland V; Nékám K; Kárteszi M
    Orv Hetil; 1989 Dec; 130(51):2723-7. PubMed ID: 2574842
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Silymarin inhibits the progression of fibrosis in the early stages of liver injury in CCl₄-treated rats.
    Clichici S; Olteanu D; Nagy AL; Oros A; Filip A; Mircea PA
    J Med Food; 2015 Mar; 18(3):290-8. PubMed ID: 25133972
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of silymarin plus vitamin E in patients with non-alcoholic fatty liver disease. A randomized clinical pilot study.
    Aller R; Izaola O; Gómez S; Tafur C; González G; Berroa E; Mora N; González JM; de Luis DA
    Eur Rev Med Pharmacol Sci; 2015 Aug; 19(16):3118-24. PubMed ID: 26367736
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.